Meridian is a primary manufacturer of specialized high-quality molecular reagents and offers solutions to a wide range of industries to diagnose and treat diseases, discover new therapeutics or develop tests for environmental, food and cosmetic safety.
Unlocking Precision in Liquid Biopsy with High-Sensitivity qPCR qPCR master mixes for oncology testing of crude blood, urine, stool and saliva samples UNPARALLELED SENSITIVITY – DETECTING DOWN TO A SINGLE COPY
However, these samples — whether from blood, urine, sputum or stool — present unique challenges due to their complexity and the low abundance of circulating biomarkers such as circulating free DNA (cfDNA), circulating tumor DNA (ctDNA), and circulating tumor RNA (ctRNA). Meridian’s ultra-sensitive qPCR master mixes are designed with enhanced inhibitor tolerance to ensure robust, accurate amplification — even in complex, inhibitor-rich liquid biopsy samples. Compatible with both purified nucleic acids and crude samples, they offer the flexibility to bypass DNA extraction when speed and efficiency are critical. This dual functionality simplifies workflows, improves sensitivity, and accelerates time to result — ideal for high-throughput liquid biopsy testing and precision oncology applications. Liquid biopsy samples contain powerful, real-time insights into disease progression, treatment response, and therapeutic resistance.
Why Liquid Biopsy
Liquid biopsy is revolutionizing cancer diagnostics by providing a minimally invasive alternative to traditional tissue biopsies. This growing innovation is transforming how cancer is detected, monitored, and treated, enabling faster and more personalized therapeutic decisions.
Blood – This is the most used bodily fluid for liquid biopsy, as it circulates through the whole of the body where it can be used to detect circulating tumor cells and DNA, allowing early cancer detection and monitoring. Urine – A rich source of cfDNA, miRNA, and tumor-derived RNA, particularly useful for bladder, prostate, and kidney cancers.
Stool – Contains shed tumor cells and DNA, providing a promising approach for colorectal cancer screening. Saliva – Contains biomarkers like MMP-9 and Chemerin, supporting non-invasive detection of oral squamous cell carcinoma (OSCC).
Liquid Biopsy: Supporting Cancer Care from Diagnosis to Monitoring
Tumor Heterogeneity
Real-Time Therapy Monitoring
Detection of Therapeutic Resistance Mechanisms
Patient Stratification & Therapeutic- Selection
Prognostic Assessment & Relapse Prediction
Early Cancer Detection & Screening
& Clonal Evolution Analysis
(MRD – Minimal Residual Disease)
Non-invasively assess tumor evolution over time via serial sampling.
Track treatment response and detect trace levels of residual disease post-therapy.
Monitor emerging mutations that may confer resistance to ongoing treatments.
Estimate disease progression or recurrence risk, including metastatic potential.
Guide targeted therapies based on tumor-specific genetic or epigenetic alterations.
Identify tumor-derived nucleic acids before symptoms appear.
www.MeridianBioscience.com/lifescience
Innovative Solutions for Oncology Assay Development
• Accelerate your development pipeline with qPCR technologies designed to meet the complex demands of oncology-focused liquid biopsy assays. Streamline Sample Prep – Work directly from crude lysates (blood, urine, stool, saliva) with inhibitor-tolerant formulations, removing the need for extraction. • Achieve Ultra-Sensitive Detection – Detect low-abundance ctDNA, ctRNA, or other tumor- derived nucleic acids — even in challenging matrices. • Build with Flexibility – Works with crude or purified inputs and is formulated for lyophilization or air-drying to support point-of-care (POC) applications, enhancing accessibility and ease of deployment. Key Considerations to Future-Proof Your Assay Development • Can your assay be miniaturized using microfluidics for high-efficiency, low-volume workflows? • Is it adaptable for home-based or point-of-care (POC) monitoring, such as MRD applications? • Would ambient temperature stability enhance global accessibility and simplify logistics?
Other than blood, are you researching biomarkers that may be detectable in urine or even stool samples?
Meridian’s scientists have taken out the complexity that comes with working with various sample types, thereby allowing you to focus on what really matters!
Ordering Information
Specimen Type
qPCR Mixes
Genotyping Mixes
Isothermal Mixes
Detect DNA & RNA using LAMP for rapid POC solutions
Detect tumor markers in ctDNA, cfDNA, ctRNA
Detect SNPs & mutations
• Air-Dryable TM Direct qPCR & RT-qPCR (MDX092/121) • Lyo-Ready Direct qPCR & RT-qPCR (MDX122/123) • Lyo-Ready AOF dUTP qPCR & RT-qPCR (MDX322/323) • Air-Dryable TM Direct qPCR & RT-qPCR (MDX150/151) • Lyo-Ready Direct qPCR & RT-qPCR (MDX152/153) • Lyo-Ready AOF dUTP qPCR & RT-qPCR (MDX352/353) • Air-Dryable TM Direct qPCR & RT-qPCR (MDX140/141) • Lyo-Ready Direct qPCR & RT-qPCR (MDX142/143) • Air-Dryable TM Direct qPCR & RT-qPCR (MDX130/131) • Lyo-Ready Direct qPCR & RT-qPCR (MDX132/133) • Lyo-Ready AOF dUTP qPCR & RT-qPCR (MDX332/333)
• Air-Dryable TM Direct DNA LAMP (MDX126) • Lyo-Ready Direct DNA & RNA LAMP (MDX124/125)
• Lyo-Ready Genotyping Direct qPCR (MDX128)
Blood
• Lyo-Ready Genotyping Direct qPCR (MDX158)
• Lyo-Ready Direct DNA & RNA LAMP (MDX154/155)
Urine
• Lyo-Ready Genotyping Direct qPCR (MDX148)
• Lyo-Ready Direct DNA & RNA LAMP (MDX144/145)
Stool
• Lyo-Ready Direct DNA & RNA LAMP (MDX134/135)
Saliva
• Lyo-Ready Genotyping Direct qPCR (MDX168)
FFPE
Meridian’s advanced qPCR formulations help you move faster — from concept to clinic — by simplifying liquid biopsy workflows and supporting innovation in precision oncology.
Ordering information: USA 5171 Wilfong Road Memphis, Tennessee 38134 Phone: +1 901-382-8716 Fax: +1 901-333-8223
Email: info@meridianlifescience.com Orders: orders@meridianlifescience.com www.MeridianBioscience.com/lifescience
Connect with us:
ISO 13485 Certified
06/25
Page 1 Page 2Powered by FlippingBook